Neurogene Inc (NGNE NASDAQ) stock market data APIs
$35.8343
-0.35(-1%)
as of August 14, 2026
Try our APIs with
free plan!
Neurogene Inc Financial Data Overview
Price chart is built with
Anychart
Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of Edinburgh, Virovek, Inc., Sigma-Aldrich Co. LLC., and Leland Stanford Junior University. The company was founded in 2018 and is headquartered in New York, New York.
Prev. Close
35.8343
Open
35.4815
High
36.3279
Low
34.4572
52 wk Range
15.93-43.66
Market Cap
723 M
Shares Outstanding
20 011 K
EPS
-1.53
Beta
1.95
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Neurogene Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Neurogene Inc data using free add-ons & libraries
Get Neurogene Inc Fundamental Data
Neurogene Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -117 990 000
- Earnings Per Share: -5
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-08-11
- EPS/Forecast: -1.4
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Neurogene Inc News
New
Newleos Names Rohan Palekar as Board Chairman
– Prominent biotech leader and former Chief Executive Officer of 89bio joins Newleos Board of Directors – BOSTON, July 28, 2026--(BUSINESS WIRE)--Newleos Therapeutics, Inc., a clinical-stage biot...
Neurogene Reports Positive Long-Term Phase 1/2 Data For Rett Syndrome Gene Therapy
(RTTNews) - Neurogene Inc. (NGNE) on Monday reported positive long-term data from its Phase 1/2 study of NGN-401 in females with Rett syndrome, a rare neurological disorder that primarily affects girl...
Neurogene to Participate in Stifel 2026 Virtual CNS Forum
NEW YORK, March 11, 2026--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurologic...
Block upgraded, Duolingo downgraded: Wall Street's top analyst calls
The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: ...
Get Neurogene Inc fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
